Hallendale Beach, Florida

TemPo Studies

**All eligible study participants will receive at no cost:** • Study-related consultation and care • Study visits, tests, assessments, and procedures • Study drugs (investigational drug or placebo)

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, as well as up to 3.5-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor necrosis factor alpha (TNFa) therapy. Novartis Pharmaceuticals 1-888-669-6682 ClinicalTrials.gov identifier: NCT01989468

The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET)

ALZ-NET collects data from individuals who are being evaluated for treatment or those receiving novel (since 2021) FDA-approved therapies for Alzheimer’s disease. ALZ-NET will track clinical, safety and long-term health outcomes of individuals in real-world settings from a variety of backgrounds and communities. This network is sponsored by the Alzheimer’s Association and managed by the American College of Radiology. Why join ALZ-NET? This is a voluntary health care provider-enrolled patient network, but with patients’ willingness to provide data on their Alzheimer's treatment and care, ALZ-NET researchers can learn about real world patterns in diagnosing and treating Alzheimer’s disease. By understanding patterns in care today, ALZ-NET can help health practitioners treat Alzheimer’s disease now and in the future. ALZ-NET aims to be a resource for evidence gathering, information sharing, and education across clinical and research communities to support and improve care of individuals living with Alzheimer’s disease. What is expected by participating in ALZ-NET? ALZ-NET does not require any additional procedures to be completed outside of the care a patient should otherwise be receiving. Participants will visit their care provider as they normally would without participating in ALZ-NET. ALZ-NET provides resources and recommendations for best practices that your provider may choose to implement in your care plan. Once registered, participation in ALZ-NET continues for as long as consent is provided and care is being received by the care provider. All care that is provided will be charged to the patient’s health insurance provider. Standard co-payments will remain the patient’s responsibility, as they would without participating in ALZ-NET. How can I participate? ALZ-NET does not require any additional effort on a participant’s behalf other than routinely visiting your health practitioner. Your health practitioner will advise if you are eligible to participate in ALZ-NET. Your health practitioner needs to be located at an active enrolled ALZ-NET site. If your provider is not actively participating in ALZ-NET, you can search our directory for a provider that is participating as ALZ-NET continues to expand to sites across the country. How to find a site To FIND A PARTICIPATING HEALTH PRACTITIONER Go to “Find a Site” at alz- net.org[ https://www.alz-net.org/Find-a-Site](https://www.alz-net.org/Find-a- Site) Search for a health practitioner who is participating in ALZ-NET in your state or near your ZIP code. If you need further assistance locating a participating site near you, please call 866-507-7254

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

This study is designed to assess the ability of K0706 to slow the progression of PD. Preclinical animal model data have already demonstrated that K0706 has neuroprotective activity, but further development will require human clinical experience. This study will also allow determination of safety and tolerability of K0706 over many months in subjects with PD.